Ovarian Cancer
Jun 11, 2024
Immune-modulation nutrition did not result in fewer complications in patients undergoing radical cystectomy, results from phase 3 SWOG S1600 trial showed. However, a trend was observed toward fewer pa...
Oct 25, 2023
Atezolizumab plus chemotherapy and maintenance niraparib in late-relapsing recurrent chemotherapy-sensitive ovarian cancer does not significantly improve outcomes. Standard therapy for ovarian ...
Sep 14, 2022
Addition of maintenance olaparib to bevacizumab provides a clinically meaningful overall survival benefit in patients who are HRD-positive, results from the final analysis of the PAOLA-1 trial show. ...
May 23, 2022
Hybrid drugs containing ferrocene and phenol residues, whose π systems are not conjugated with each other, exhibit potent anticancer activity as previously reported. Few important open questions are ...
May 16, 2022
Emerging evidence identifies enhancer RNAs (eRNAs) as a class of regulatory ncRNAs that can contribute to the transcription of target genes. In this study, we used an integrated data analysis method t...
May 09, 2022
Previous reports indicate that long intergenic non-coding RNA LINC00665 naturally occurred vital effects in various cancers. Herein, the role of LINC00665 in ovarian cancer progress was explored. We f...
May 09, 2022
SAD1/UNC84 domain protein-2 (SUN2) plays a tumor suppressor role in various types of cancer by inhibiting cancer cell proliferation, migration and promoting apoptosis. However, the post-translational ...
May 02, 2022
Brain metastases from ovarian cancer remain rare and the appropriate treatment is unknown. We investigated survival outcomes following salvage chemotherapy before and after bevacizumab approval to eva...
May 02, 2022
Ovarian clear cell carcinoma (OCCC) is one of the most lethal types of ovarian cancer. Early-stage OCCC can be cured by surgery; however, advanced-stage disease shows poor prognosis due to chemoresist...
Apr 29, 2022
Chemotherapy can have a variety of adverse consequences, including chemotherapy-induced cognitive impairment and the term "chemobrain. The research aimed to gain a better understanding of patient-repo...
Apr 29, 2022
Open surgery has become the standard technique for radical hysterectomy (International Federation of Gynecology and Obstetrics (FIGO) 2018 IA1 with lymphovascular space invasion-IIA1). The goal of the...
Apr 27, 2022
Black women experience higher mortality from endometrial cancer (EC) than White women, according to published data, and potential reasons for this disparity include increased rates of obesity and more...
Apr 25, 2022
The collection and evaluation of family health history in a clinical setting presents an opportunity to discuss cancer risk, tailor cancer screening recommendations, and identify people with an increa...
Apr 18, 2022
Although the use of PARP inhibitor has received considerable amount of attention in ovarian cancer, PARP inhibitor resistance still emerges with disease progression. PI3K/AKT pathway inhibitors have b...
Apr 11, 2022
Malignant ascites is a common clinical problem in ovarian cancer. NK cells are present in the ascites, but their antitumor activity is inhibited. The underlying mechanisms of the inhibition have yet t...
Apr 04, 2022
Epithelial ovarian cancer (EOC) exhibits strong dependency on the tricarboxylic acid (TCA) cycle and oxidative phosphorylation to fuel anabolic process. Here, we show that malate dehydrogenase 2 (MDH2...
Mar 28, 2022
TMEFF1 is a newly discovered protein involved in the physiological functions of the central nervous system, embryonic development, and other biological processes. Our previous study revealed that TMEF...
Mar 21, 2022
The tumor microenvironment hosts antibody-secreting cells (ASCs) associated with a favorable prognosis in several types of cancer. Patient-derived antibodies have diagnostic and therapeutic potential;...
Mar 14, 2022
Ovarian cancer stem-like cells (CSCs) have been implicated in tumor recurrence, metastasis, and drug resistance. Accumulating evidence has demonstrated the antitumor effect of plasma-activated medium ...
Mar 14, 2022
Dysregulated long noncoding RNA (lncRNA) HLA-F-AS1 is depicted in numerous cancers. However, its function in ovarian cancer has yet to be clarified. LncRNA HLA-F-AS1, miR-21-3p, and PEG3 expressions i...